Complete Mapping of Divergent Amino Acids Responsible for Differential Ligand Binding of Folate Receptors alpha  and beta *

Karen M. Maziarz, Hugo L. MonacoDagger , Feng Shen, and Manohar Ratnam§

From the Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo, Ohio 43614-5804 and the Dagger  Department of Genetics, University of Pavia, Via Abbiategrasso 207, 27100 Pavia, Italy

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

The folate receptor (FR) type alpha  may be distinguished from FR-beta by its higher affinity for the circulating folate coenzyme, (6S)-5-methyltetrahydrofolate (5-CH3H4folate), and its opposite stereospecificity for reduced folate coenzymes. Previous studies showed that a single leucine to alanine substitution at position 49 of the mature protein sequence is responsible for the functional divergence of FR-beta (Shen, F., Zheng, X., Wang, H., and Ratnam, M. (1997) Biochemistry 36, 6157-6163); however, the results also indicated that the minimum requirement for conversion of FR-beta to the functional equivalent of FR-alpha should include amino acid substitution(s) downstream of residue 92 in addition to mutation of L49A. To pinpoint those residues, chimeric FR-beta L49A/FR-alpha constructs including progressively shorter segments of FR-alpha downstream of position 92 as well as selected point mutants were studied. Simultaneous substitution of Leu-49, Phe-104, and Gly-166 in FR-beta with the corresponding FR-alpha residues Ala, Val, and Glu, respectively, reconstituted the ligand binding characteristics of FR-alpha . The results also exclude a role for other residues in FR-alpha in determining its functional divergence. A homology model of FR-alpha based on the three-dimensional structure of the chicken riboflavin-binding protein is used to show the position of residues 49, 104, and 166 in relation to the hydrophobic cleft corresponding to the riboflavin-binding pocket.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

The cell surface receptor for folic acid (folate receptor, FR)1 has the ability to mediate physiologic folate uptake and to transport novel antifolate drugs and folate conjugates (1-20). The receptor is a current major focus as a tumor target for multiple experimental approaches in cancer therapy. Several studies have shown that FR, when expressed at high levels, could offer the preferred uptake route of novel classes of antifolate drugs that target glycineamide ribonucleotide formyltransferase and thymidylate synthase (3-6). Taking advantage of the non-destructive nature of FR-mediated internalization of folate-coupled macromolecules (7, 8), cytotoxins such as momordin, pseudomonas exotoxin, and maytansinoids were shown to produce selective killing in FR-rich cells (9-12). Furthermore, the toxicity of such conjugates was dependent upon receptor density on the cell surface (10). Folate-conjugated radiopharmaceuticals also appear to offer a means of tumor imaging/radiation therapy (13-16). Folate-coated liposomes were shown to selectively target FR-rich tumor cells (17) and selective killing of the malignant cells was obtained by encapsulating doxorubicin in the liposomes (18). By a similar strategy, it was possible to deliver antisense oligonucleotides against the epidermal growth factor receptor to FR-rich tumor cells (19). Furthermore, selective folate-mediated targeting of an adenoviral vector to FR-rich tumor cells has been achieved in the presence of an antibody to ablate the endogenous viral tropism (20).

The mechanism of folate uptake via FR has been shown to occur by an endocytic process (7-8, 21-25). The three known isoforms of FR, types alpha  (26, 27), beta  (28), and gamma /gamma ' (29), bind folic acid with a high affinity (Kd < 1 nM) and a stoichiometry of 1:1 (30). The mature proteins are 68-79% identical in amino acid sequence, ranging in length from 220 to 236 amino acids. The proteins have either two (FR-beta , FR-gamma ) or three (FR-alpha ) sites of N-glycosylation which cumulatively contribute to their proper protein folding and intracellular trafficking but are not required for folate binding (31). FR-alpha and FR-beta are attached to the cell surface by a glycosylphosphatidylinositol membrane anchor (26, 32-34), whereas, FR-gamma and a truncated form of the protein, FR-gamma ' are constitutively secreted (35). The sites of glycosylphosphatidylinositol modification in FRs-alpha and -beta are Ser209 and Asn211, respectively (34).

FR isoforms are expressed in a tissue specific manner and are selectively overexpressed in certain malignant tissues. FR-alpha is specific for particular epithelial cells and is vastly up-regulated in ovarian and uterine carcinomas (36-39). FR-beta is not expressed at significant levels in most normal tissues with the known exceptions of placenta, spleen, thymus, and neutrophils (39, 40). Overexpression of FR-beta was observed in some malignancies of non-epithelial origin including myeloid leukemia (29, 40). FR-gamma and FR-gamma ' are specific for hematopoietic tissues, particularly lymphoid cells (35).

FR-alpha and FR-beta from both human (41) and murine (42) sources have opposite stereospecificities for the reduced coenzyme forms of folate, 5-methyltetrahydrofolate (5-CH3H4folate) (Fig. 1) and 5-formyltetrahydrofolate (5-CHOH4folate). In contrast to FR-alpha , FR-beta preferentially binds to the unphysiologic (6R)-diastereoisomers of these compounds relative to their physiologic (6S)-diastereoisomers. FR-beta also exhibits a significantly lower affinity relative to FR-alpha for the (6S)-diastereoisomer of 5-CH3H4folate, the major circulating form of the vitamin. In addition, FR-beta has a lower affinity for a variety of antifolate compounds compared with FR-alpha (41).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Structures of the (6S)- (top) and (6R)- (bottom) diastereoisomers of 5-methyltetrahydrofolate (N5-methyl-5,6,7,8-tetrahydropteroyl glutamic acid).

The tissue specificity of FR isoforms and their elevation in malignant tissues may be an important factor in selective targeting of malignant cells via FR-mediated uptake of novel antifolates and folate conjugates. It is therefore of significance to understand the structural basis for the functional difference between the membrane anchored FR isoforms. We have previously demonstrated a relatively unambiguous approach to identify peptide segments or specific amino acid residues that could account for the functional differences between FR-alpha and FR-beta (43). The approach takes advantage of the fact that FR-alpha and FR-beta are structurally homologous, and therefore chimeric constructs of the two proteins may be expected to result in functional proteins that could be characterized; by systematic construction of a series of such chimeras in which progressively shorter peptides of one protein are substituted in the other protein, residues that are significant for a specific functional difference may be mapped while simultaneously excluding a role for other residues. In this manner we have previously demonstrated that the functional divergence of FR-beta from FR-alpha is due to Leu49 in FR-beta (43); substitution of Ala49 in FR-alpha with Leu conferred the ligand binding characteristics of FR-beta . However, conversion of FR-beta to the functional equivalent of FR-alpha could only be accomplished when, in addition to the reciprocal mutation of L49A, the sequence downstream of residue 92 in FR-alpha was substituted in FR-beta . Thus, the functional divergence of FR-alpha from FR-beta could possibly be accounted for by one or more residues downstream of position 92 in addition to Ala49. The purpose of this study is to identify those residues in FR-alpha .

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Mutagenesis and Recombinant Plasmids-- Chimeric constructs of FR-alpha and FR-beta were made by utilizing natural restriction sites or by creating restriction sites by the polymerase chain reaction using Vent DNA polymerase (New England Biolabs) and the cDNAs for FR-alpha or FR-beta as template. Oligonucleotides (Life Technologies, Inc.) were designed in two different ways in order to construct the appropriate recombinant proteins. In cases where no suitable restriction site was found, complementary primers containing an appropriate restriction site or point mutation were used in conjunction with upstream and downstream primers containing restriction sites. Alternatively, mutagenic oligonucleotides were used as end primers to amplify the desired fragment. All of the synthetic oligonucleotides (Table I) were designed to contain restriction sites or point mutations without undesirable alterations of amino acid sequence. The polymerase chain reaction products were first digested at both ends with the appropriate restriction enzymes and subcloned into the plasmid pcDNA1 (Invitrogen) containing the FR-beta L49A mutant cDNA. The recombinant plasmid was amplified in Escherichia coli MC1061/p3 and purified using the Qiagen plasmid kit (Qiagen). The entire cDNA sequence was verified by dideoxy sequencing using AmpliCycle Sequencing Kit (Perkin-Elmer).

                              
View this table:
[in this window]
[in a new window]
 
Table I
5'-3' Oligonucleotides and restriction sites used to generate the chimeric constructs of FR-alpha and FR-beta

Cell Culture and Transfection-- Human 293 fibroblasts were maintained in Eagle's minimal essential media (Irvine Scientific) supplemented with fetal bovine serum (10% v/v), penicillin (100 units/ml), and streptomycin (100 µg/ml). The cells were transfected using either LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's protocol or by the use of calcium phosphate (44). Transfection efficiencies were normalized to a co-transfected beta -galactosidase standard and found to be relatively uniform.

Preparation of Crude Plasma Membranes-- Crude plasma membranes were prepared essentially as described (41). Confluent cultures of transfected 293 cells were washed at 4 °C initially with PBS (10 mM sodium phosphate, pH 7.5, 150 mM NaCl) followed by acid wash (10 mM sodium acetate, pH 3.5, 150 mM NaCl) to remove endogenously bound folate from cell surface receptors and a subsequent PBS wash. The cells were scraped off the plates and suspended in lysis buffer (1 mM NaHCO3, 2 mM CaCl2, 5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, pH 7.7), incubated at 4 °C for 30 min and then frozen at -70 °C. The cells were then thawed and homogenized by 60 strokes in a glass Dounce homogenizer. The homogenate was centrifuged at 1000 × g for 5 min to sediment nuclei and cell debris. The supernatant was then centrifuged at 4000 × g for 45 min to sediment the membranes. The membranes were washed in cold (4 °C) acid buffer by resuspending in the buffer using a 1-ml syringe followed by sedimentation. After an additional wash in PBS the membrane preparation was resuspended in PBS containing 1 mM phenylmethylsulfonyl fluoride.

[3H]Folic Acid Binding Assay-- [3H]Folic acid (Morevek, specific radioactivity 37 Ci/mmol, 2.5 pmol/assay tube) was mixed with a membrane suspension in 0.5 ml of PBS and incubated for 60 min at room temperature on a rotary shaker. The membranes were sedimented at 12,000 × g for 30 min at 4 °C and washed once with PBS. The membranes were then dissolved in scintillation fluid (Eccoscint H, Fisher Scientific) and the associated radioactivity counted in a Beckman LS3801 liquid scintillation counter. Membranes from untransfected cells as well as membranes preincubated with excess unlabeled folic acid were used as negative control.

The [3H]folic acid binding assay for FR on whole cells in 6-well tissue culture dishes was performed as described previously (34). The cells were washed sequentially at 4 °C with PBS, acid buffer, and again with PBS. The cells were then incubated in a 1-ml solution of PBS containing 3 pmol of [3H]folic acid and 9 pmol of unlabeled folic acid and incubated for 30 min at 4 °C. The cells were then washed two times with PBS. Ice-cold acid buffer was used to remove bound folate and the amount of [3H]folic acid measured by liquid scintillation counting. Untransfected cells as well as membranes preincubated with excess unlabeled folic acid were used as negative controls.

Inhibition Studies-- The relative affinities of (6S)- or (6R)-diastereoisomers of 5-CH3H4folate for wild-type or mutant FRs were determined by measuring the IC50 values for the compounds for inhibition of [3H]folic acid binding using a range of reduced folate concentrations (1-500 nM). A fixed concentration (2 nM) of [3H]folic acid was used in these experiments. The assays were carried out as described above for the binding of [3H]folic acid to FR-rich membranes either in the absence of inhibitor or with simultaneous addition of inhibitor and [3H]folic acid. IC50 values were calculated using the Inplot computer program (GraphPad Software Inc., Version 4.03).

Structural Modeling-- A sequence alignment between cRBP and FR-alpha was performed using the program ClustalW (45). A homology model of the conserved ligand-binding domain (peptide 12-188) was generated with the modeling package Quanta (Molecular Simulations) using the cRBP crystal structure (46) as template. Nonconserved residue replacements were carried out using the mutated function within Quanta. The three insertions all occur in the surface loop region, and their conformations were modeled using a main chain data base and side chain rotamer search procedure in program O (47). The model was used for the rotation and translation search in molecular replacement program Amore (48) against the x-ray diffraction data of FR-alpha .2 The resulting model was further refined by rigid-body refinement and energy-minimization calculations in X-PLOR (49). Finally, the stereochemical quality of the model was confirmed using Procheck (50). The surface accessibility of residues was calculated in Quanta using the Lee and Richards algorithm (51) with the probe radius set as 1.4 Å.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

To determine the role of individual amino acids of FR-alpha responsible for its functional variance from FR-beta , the general strategy adopted in this study was to examine the effect of substituting peptides or amino acids of FR-alpha at corresponding locations in FR-beta . The basic premise of this approach is that one or a combination of a few amino acids in FR-alpha are solely responsible for its functional divergence and that they will similarly influence the function of FR-beta when substituted in it. For the results of such studies to be most meaningful, it is also important that the mutations not interfere with protein folding and cell surface expression of a functional receptor. Indeed it may be seen in the following sections that all of the FR-beta mutants were functional and showed expression levels comparable to that of the wild-type protein. The focus of the functional analysis of the mutant proteins was to test for increase in affinity for (6S)-5-CH3H4folate and absence of stereospecificity for (6R)-5-CH3H4folate, both distinguishing characteristics of FR-alpha . It was previously demonstrated (43) that substitution of Ala49 in FR-alpha with Leu, the corresponding residue in FR-beta , conferred FR-beta -like characteristics. Conversion of FR-beta to the functional equivalent of FR-alpha by substituting the sequence downstream of position 92 of FR-alpha was only possible if Leu49 was simultaneously mutated to Ala. Therefore in the following studies, all of the sequence substitutions and mutations were made downstream of position 92 in FR-beta L49A.

Functional Mapping of FR-alpha Peptides Downstream of Position 92-- cDNA constructs were made to encode chimeric proteins in which portions of the carboxyl terminus downstream of amino acid 92 in the FR-beta L49A mutant were replaced by the corresponding peptides from FR-alpha . The initial chimeric proteins generated were FR-beta 1-139/alpha 140-232(L49A) and FR-beta 1-92/alpha 93-139/beta 140-236(L49A) (Fig. 2). The mutants were transiently expressed in human 293 fibroblasts. Membrane preparations from the transfected cells were tested for their relative affinities for the (6S)- and (6R)-diastereoisomers of 5-CH3H4folate (Fig. 2). Both chimeric proteins showed approximately 10-fold greater affinity for (6S)-5-CH3H4folate than either the wild-type FR-beta or FR-beta L49A; however, the values were approximately 4-fold lower than that of wild-type FR-alpha . These results appeared to suggest that amino acid residues from both segments of FR-alpha , i.e. peptides 93-139 and 140-232, would be required to completely confer FR-alpha -like ligand binding characteristics to FR-beta L49A.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 2.   Characterization of chimeric and mutant forms of FR for mapping functional residues in peptide 93-139. The horizontal bars represent the complete or partial polypeptide sequence of FR-alpha (open bars) or FR-beta (hatched bars). The numbers on the diagram indicate the positions of amino acid residues in the protein after processing of the leader peptide. The columns at the right indicate the expression levels of the recombinant proteins in terms of the amount of [3H]folic acid bound at the cell surface, the IC50 values for the diastereoisomers of 5-CH3H4folate, and the wild-type FR isoform to which they correspond functionally. The term intermediate refers to relative affinities for (6S)-5-CH3H4folate that are in between those of FR-alpha and FR-beta . Transfection efficiencies were normalized to a co-transfected beta -galactosidase standard. ND indicates not determined. From multiple determinations of IC50 values, percent error was <25.

Role of Divergent Amino Acids in Peptide 93-139 of FR-alpha -- To further map the functionally relevant amino acid(s) within peptide 93-139, additional chimeric constructs in which shorter segments of FR-alpha were incorporated into the FR-beta L49A mutant were designed (Fig. 2) to produce: FR-beta 1-92/alpha 93-125/beta 126-236(L49A) and FR-beta 1-92/alpha 93-115/beta 116-236(L49A). These two constructs showed functional characteristics similar to FR-beta 1-92/alpha 93-139/beta 140-236(L49A). Furthermore, chimeras in which peptides 126-232 and 116-232 of FR-alpha were substituted in FR-beta L49A (Fig. 2) behaved similar to FR-beta 1-139/alpha 140-232(L49A). It is therefore reasonable to conclude that the peptide sequence 116-139 in FR-alpha has little significance in the differential ligand specificities of the FR isoforms and that peptide 93-115 must contain functionally significant residues.

Among the 23 residues in peptide 93-115, only four, at positions 96, 104, 106, and 115, are unconserved in FR-alpha . As noted previously, the two known murine FR isoforms type 1 and type 2 correspond to the human FR-alpha and FR-beta , respectively, in terms of their ligand binding characteristics. Alignment of the amino acid sequences of peptides 93-115 of FRs from both human and murine (52) sources (Fig. 3) indicates that amino acid residues at positions 96 and 106 are conserved in the murine FR isoforms. Furthermore, the amino acid at position 115 is the same (glutamic acid) in both human FR-beta and murine FR-1. Therefore if one assumes the presence of analogous structure-function relationships among human and murine FRs, it would appear that the likely candidates contributing to functional differences between FR-alpha and FR-beta do not occur at positions 96, 106, and 115. Indeed, when these amino acids in FR-beta 1-92/alpha 93-115/beta 116-236(L49A) were individually changed back to the corresponding residues of FR-beta , it was apparent that the amino acids at positions 96, 106, and 115 were inconsequential to the functional differences between FR-alpha and FR-beta (Fig. 2); mutation of the amino acid at position 104, however, reverted the characteristics of the chimera to those of FR-beta L49A. Furthermore, the double mutant, FR-beta L49A,F104V, showed approximately 10-fold higher affinity for (6S)-5-CH3H4folate compared with FR-beta (Fig. 2). These results clearly indicate that valine at position 104 in FR-alpha contributes partially to its distinct ligand binding properties.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Alignment of amino acid sequences of human (26) and murine (52) FRs between amino acids 93 and 115. The numbers indicate positions of amino acids. Residues that are different between FR-alpha and FR-beta are in bold face.

Indentification of a Functionally Relevant Residue Downstream of Position 139 in FR-alpha -- From the foregoing results it appears that to achieve complete conversion of FR-beta to the functional equivalent of FR-alpha , it is necessary to substitute one or more residues downstream of position 139 in addition to creating L49A and F104V mutations in FR-beta . To identify those residue(s), chimeras were first constructed in which FR-alpha peptide sequences 140-155 or 156-232 were substituted in the double mutant, FR-beta L49A,F104V (Fig. 4). FR-beta 1-139/alpha 140-155/beta 156-236(L49A,F104V) showed properties similar to those of FR-beta L49A,F104V (Fig. 4). FR-beta 1-155/alpha 156-232(L49A,F104V), on the other hand, exhibited ligand binding specificity similar to FR-alpha (Fig. 4) thus mapping the relevant amino acid(s) to the sequence downstream of position 155. Since the carboxyl-terminal peptide downstream of the glycosylphosphatidylinositol modification site (Ser209) in FR-alpha is absent in the mature protein (34), further mapping was restricted to peptide 156-208. Within this peptide only seven residues are unconserved between FR-alpha and FR-beta . Alignment of the amino acid sequence of human and murine (52) FR isoforms (Fig. 5) shows that only three amino acids (positions 166, 167, and 191) are conserved between human FR-alpha and murine FR-1 and between human FR-beta and murine FR-2. It was therefore undertaken to test the significance of those residues in contributing to functional differences between FR-alpha and FR-beta . Mutation of Leu167 or Ser191 in FR-beta L49A,F104V to Ile and Pro, respectively, the corresponding residues in FR-alpha , did not significantly alter the properties of the protein (Fig. 4). However, when Gly166 was substituted with Glu, the corresponding residue in FR-alpha , the ligand binding characteristics of FR-alpha were fully reconstituted in FR-beta L49A,F104V. Taken together, the results of this study indicate that alanine at position 49, valine at position 104, and glutamic acid at position 166 act synergistically to produce the distinguishing ligand binding characteristics of FR-alpha compared with FR-beta .


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Characterization of chimeric and mutant forms of FR for mapping functional residues downstream of position 139. The horizontal bars represent the complete or partial polypeptide sequence of FR-alpha (open bars) or FR-beta (hatched bars). The numbers on the diagram indicate the positions of amino acid residues in the protein after processing of the leader peptide. The columns at the right indicate the expression levels of the recombinant proteins in terms of the amount of [3H]folic acid bound at the cell surface, the IC50 values for the diastereoisomers of 5-CH3H4folate, and the wild-type FR isoform to which they correspond functionally. The term intermediate refers to relative affinities for (6S)-5-CH3H4folate that are in between those of FR-alpha and FR-beta . Transfection efficiencies were normalized to a co-transfected beta -galactosidase standard. From multiple determinations of IC50 values, percent error was <25.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 5.   Alignment of amino acid sequences of human (26) and murine (52) FRs between amino acids 155 and 208. The numbers indicate positions of amino acids. Residues that are different between FR-alpha and FR-beta are in bold face. The dotted lines indicate amino acid sequences that are identical between human FR-alpha and FR-beta .

A Structural Model of FR-- FR shows considerable (~30%) amino acid sequence identity with the 219-residue chicken riboflavin-binding protein (cRBP) (53). The amino acid sequence alignment of the two proteins has been reported (46). The conserved amino acids include the 16 cysteine residues in FR and 6 tryptophan residues. The nine pairs of cysteine residues in cRBP form disulfide bridges to maintain its structural fold (54). In the three-dimensional structure of cRBP, the conserved tryptophan residues at positions 61, 91, 117, 131, 135, and 168 and tyrosine 82 stack into a hydrophobic pocket for binding the aromatic ring of the ligand (46). The sequence similarity between FR and cRBP implies structural similarity between these two protein families. We have built a homology model of the folate-binding domain of FR-alpha (Fig. 6) based on the crystal structure of cRBP (46). In the model, residues 104 and 166 are 13.9 Å apart and are respectively located inside and at the entrance of a cleft that corresponds to the ligand-binding pocket in cRBP. Residue 49 is peripheral to this cleft, 24.3 Å away from residue 104. The solvent accessible surface area of residues 49, 104, and 166 are 8.61, 27.5, and 91.7 Å2, respectively, and their side chain fractional accessibilities are 0.11, 0.20, and 0.61, respectively. The model indicates that while conserved tryptophan and tyrosine residues may contribute to the affinity of ligand binding, residues 49, 104, and 166 may be expected to play either a direct or an indirect role in causing the differential affinities and stereospecificities of FR-alpha and FR-beta for the coenzyme forms of folate and for antifolate drugs.


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 6.   Homology model of the folate-binding domain of FR-alpha based on the crystal structure of the chicken riboflavin-binding protein. The protein backbone is colored by the secondary structure: alpha  helices in green, beta  sheets in blue, loops in yellow. Ala49, Val104, and Glu166 are highlighted with space-filling models and colored in red. The folate binding pocket is indicated by the arrow.


    ACKNOWLEDGEMENTS

We thank Dr. Faming Zhang for help with modeling work and Michael Brun for assistance with graphics.

    FOOTNOTES

* This work was supported by National Institutes of Health, NCI, Grant R29CA57598 and a grant from Eli Lilly & Co. (to M. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed.

2 F. Zhang, M. Ratnam, J. Miller, C. Shih, and R. Schevitz, unpublished results.

    ABBREVIATIONS

The abbreviations used are: FR, folate receptor; PBS, phosphate-buffered saline; H4folate, tetrahydrofolate; cRBP, chicken riboflavin-binding protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
  1. Jansen, G., Westerhof, G. R., Kathmann, I., Rademaker, B. C., Rijksen, G., and Schornagel, J. H. (1989) Cancer Res. 49, 2455-2459[Abstract]
  2. Henderson, G. B., and Strauss, B. P. (1990) Biochem. Pharmacol. 39, 2019-2025[Medline] [Order article via Infotrieve]
  3. Jansen, G., Schornagel, J. H., Westerhof, G. R., Rijksen, G., Newell, D. R., and Jackman, A. L. (1990) Cancer Res. 50, 7544-7548[Abstract]
  4. Jansen, G., Westerhof, G. R., Kathmann, I., Rijksen, G., and Schornagel, J. H. (1991) Cancer Chemother. Pharmacol. 28, 115-117[Medline] [Order article via Infotrieve]
  5. Westerhof, G. R., Jansen, G., van Emmerik, N., Kathmann, I., Rijksen, G., Jackman, A. L., and Schornagel, J. H. (1991) Cancer Res. 51, 5507-5513[Abstract]
  6. Westerhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., Pinedo, H. M., and Jansen, G. (1995) Mol. Pharmacol. 48, 459-471[Abstract]
  7. Leamon, C. P., and Low, P. S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5572-5576[Abstract]
  8. Turek, J. J., Leamon, C. P., and Low, P. S. (1993) J. Cell Sci. 106, 423-430[Abstract/Free Full Text]
  9. Leamon, C. P., and Low, P. S. (1992) J. Biol. Chem. 267, 24966-24971[Abstract/Free Full Text]
  10. Leamon, C. P., and Low, P. S. (1994) J. Drug Targeting 2, 101-112[Medline] [Order article via Infotrieve]
  11. Leamon, C. P., Pastan, I., and Low, P. S. (1993) J. Biol. Chem. 268, 24847-24854[Abstract/Free Full Text]
  12. Ladino, C. A., Chari, R. V., Bourret, L. A., Kedersha, N. L., and Goldmacher, V. S. (1997) Int. J. Cancer 73, 859-864[CrossRef][Medline] [Order article via Infotrieve]
  13. Mathias, C. J., Wang, S., Lee, R. J., Waters, D. J., Low, P. S., and Green, M. A. (1996) J. Nucl. Med. 37, 1003-1008[Abstract]
  14. Mathias, C. J., Wang, S., Waters, D. J., Turek, J. J., Low, P. S., and Green, M. A. (1998) J. Nucl. Med. 39, 1579-1585[Abstract]
  15. Mathias, C. J., and Green, M. A. (1998) Nucl. Med. Biol. 25, 585-587[CrossRef][Medline] [Order article via Infotrieve]
  16. Wang, S., Luo, J., Lantrip, D. A., Waters, D. J., Mathias, C. J., Green, M. A., Fuchs, P. C., and Low, P. S. (1997) Bioconj. Chem. 8, 673-679[CrossRef][Medline] [Order article via Infotrieve]
  17. Lee, R. J., and Low, P. S. (1994) J. Biol. Chem. 269, 3198-3204[Abstract/Free Full Text]
  18. Lee, R. J., and Low, P. S. (1995) Biochim. Biophys. Acta 1233, 134-144[Medline] [Order article via Infotrieve]
  19. Wang, S., Lee, R. J., Cauchon, G., Gorenstein, D. G., and Low, P. S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3318-3322[Abstract]
  20. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T. (1996) Nat. Biotechnol. 14, 1574-1578[Medline] [Order article via Infotrieve]
  21. Kamen, B. A., Wang, M. T., Streckfuss, A. J., Peryea, X., and Anderson, R. G. W. (1988) J. Biol. Chem. 263, 13602-13609[Abstract/Free Full Text]
  22. Leamon, C. P., and Low, P. S. (1993) Biochem. J. 291, 855-860[Medline] [Order article via Infotrieve]
  23. Birn, H., Selhub, J., and Chrstensen, E. I. (1993) Am. J. Physiol. 264, 302-310
  24. Smart, E. J., Mineo, C., and Anderson, R. G. W. (1996) J. Cell Biol. 134, 1169-1177[Abstract]
  25. Wu, M., Fan, J., Gunning, W., and Ratnam, M. (1997) J. Membr. Biol. 159, 137-147[CrossRef][Medline] [Order article via Infotrieve]
  26. Lacey, S. W., Sanders, J. M., Rotherburg, K. G., Anderson, R. G. W., and Kamen, B. A. (1989) J. Clin. Invest. 84, 715-720[Medline] [Order article via Infotrieve]
  27. Elwood, P. C. (1989) J. Biol. Chem. 264, 14893-14901[Abstract/Free Full Text]
  28. Ratnam, M., Marquardt, H., Duhring, J. L., and Freisheim, J. H. (1989) Biochemistry 28, 8249-8254[Medline] [Order article via Infotrieve]
  29. Shen, F., Ross, J. F., Wang, X., and Ratnam, M. (1994) Biochemistry 33, 1209-1215[Medline] [Order article via Infotrieve]
  30. Antony, A. C. (1992) Blood 79, 2807-2820[Medline] [Order article via Infotrieve]
  31. Shen, F., Wang, H., Zheng, X., and Ratnam, M. (1997) Biochem. J. 327, 759-764[Medline] [Order article via Infotrieve]
  32. Luhrs, C. A., and Slomiany, B. L. (1989) J. Biol. Chem. 264, 21446-21449[Abstract/Free Full Text]
  33. Verma, K. S., Gullapalli, S., and Antony, A. C. (1992) J. Biol. Chem. 267, 4119-4127[Abstract/Free Full Text]
  34. Yan, W., and Ratnam, M. (1995) Biochemistry 34, 14594-14600[Medline] [Order article via Infotrieve]
  35. Shen, F., Wu, M., Ross, J. F., Miller, D., and Ratnam, M. (1995) Biochemistry 24, 5660-5665
  36. Campbell, I. G., Jones, T. A., Foulkes, W. D., and Trowsdale, J. (1991) Cancer Res. 51, 5329-5338[Abstract]
  37. Coney, L. R., Tomasetti, A., Carayannopoulos, L., Frasca, V., Kamen, B. A., Colnaghi, M. I., and Zurawski, V. R., Jr. (1991) Cancer Res. 51, 6125-6132[Abstract]
  38. Weitman, S. D., Lark, R. H., Corey, L. R., Fort, D. W., Frasca, V., Zurawski, V. R., Jr., and Kamen, B. A. (1992) Cancer Res. 52, 3396-3401[Abstract]
  39. Ross, J. F., Chauduri, P. K., and Ratnam, M. (1994) Cancer 73, 2432-2443[Medline] [Order article via Infotrieve]
  40. Ross, J. F., Wang, H., Behm, F. G., Matthew, P., Wu, M., Booth, R., and Ratnam, M. (1999) Cancer 85, 348-357[CrossRef][Medline] [Order article via Infotrieve]
  41. Wang, X., Shen, F., Freisheim, J. H., Gentry, L. E., and Ratnam, M. (1992) Biochem. Pharmacol. 44, 1898-1901[Medline] [Order article via Infotrieve]
  42. Brigle, K. E., Spinella, M. J., Westin, E. H., and Goldman, I. D. (1994) Biochem. Pharmacol. 47, 337-345[CrossRef][Medline] [Order article via Infotrieve]
  43. Shen, F., Zheng, X., Wang, J., and Ratnam, M. (1997) Biochemistry 36, 6157-6163[CrossRef][Medline] [Order article via Infotrieve]
  44. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  45. Higgins, D. G., Thompson, J. D., and Gibson, T. J. (1996) Methods Enzymol. 266, 383-402[Medline] [Order article via Infotrieve]
  46. Monaco, H. L. (1997) EMBO J. 16, 1475-1483[Abstract/Free Full Text]
  47. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgarrd, M. (1991) Acta Crystallogr. Sect. A 47, 110-119[CrossRef][Medline] [Order article via Infotrieve]
  48. Navaza, J. (1994) Acta Crystallogr. Sect. A 50, 157-163[CrossRef]
  49. Bruger, A. T. (1992) X-PLOR, Version 3.1, A System for X-ray Crystallography and NMR,, Yale University Press, New Haven, CT
  50. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thronton, J. M. (1993) J. Appl. Crystallogr. 26, 283-291[CrossRef]
  51. Lee, B., and Richards, F. M. (1971) J. Mol. Biol. 55, 379-400[Medline] [Order article via Infotrieve]
  52. Brigle, K. E., Westin, E. H., Houghton, M. T., and Goldman, I. D. (1991) J. Biol. Chem. 266, 17243-17249[Abstract/Free Full Text]
  53. Norioka, N., Okada, T., Hamazume, Y., Mega, T., and Ikenama, T. (1985) J. Biochem. (Tokyo) 97, 19-28[Abstract]
  54. Hamazume, Y., Mega, T., and Ikenaka, T. (1987) J. Biochem. (Tokyo) 101, 217-223[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.